Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer

BACKGROUND: Polo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic progression. Plk1 is upregulated in many tumor types including colorectal cancer (CRC) and portends a poor prognosis. TAK-960 is an ATP-competitive Plk1 inhibitor that has demonst...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Cancer
Päätekijät: Klauck, Peter J., Bagby, Stacey M., Capasso, Anna, Bradshaw-Pierce, Erica L., Selby, Heather M., Spreafico, Anna, Tentler, John J., Tan, Aik Choon, Kim, Jihye, Arcaroli, John J., Purkey, Alicia, Messersmith, Wells A., Kuida, Keisuke, Gail Eckhardt, S., Pitts, Todd M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2018
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5800287/
https://ncbi.nlm.nih.gov/pubmed/29402316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4036-z
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia